Seno Hiroshi, Oshima Masanobu, Ishikawa Tomo-o, Oshima Hiroko, Takaku Kazuaki, Chiba Tsutomu, Narumiya Shuh, Taketo Makoto M
Department of Pharmacology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.
Cancer Res. 2002 Jan 15;62(2):506-11.
To investigate angiogenesis during intestinal polyp development, we determined the microvessel density (MVD) in polyps of Apc knockout (Apc(Delta716)) mice, a model for human familial adenomatous polyposis. We scored MVD also in several compound mutants carrying Apc(Delta716), namely, mice with an additional mutation in Smad4, in which the polyps progress into invasive adenocarcinomas; mice with a cyclooxygenase (COX)-2 gene (Ptgs2) mutation, in which adenoma growth is suppressed; and mice with prostaglandin E(2) EP receptor gene mutations. In both simple Apc(Delta716) and compound Apc(Delta716) Smad4 mutants, MVD increased in a polyp size-dependent manner only in the polyps expanded beyond a threshold of about 1 mm in diameter. These results indicate that tumor angiogenesis is stimulated only after tumors grow to a certain size, and this angiogenic switch is common to both benign adenomas and malignant adenocarcinomas. In Apc(Delta716) polyposis attenuated by the COX-2 gene mutation, in contrast, MVD did not increase even in polyps larger than 1 mm. The same phenomenon was observed in the compound mutant mice with Apc(Delta716) and the EP(2) receptor gene mutations, but not in other EP compound mutants. We also immunohistochemically studied COX-2 and angiogenic factors, vascular endothelial growth factor and basic fibroblast growth factor. Interestingly, expression of these proteins was also increased in polyps larger than 1 mm. These results suggest that, in both benign and malignant mouse intestinal tumors, stromal expression of COX-2 results in elevated prostaglandin E(2) levels that stimulate cell surface receptor EP(2), followed by induction of vascular endothelial growth factor that causes tumor angiogenesis.
为了研究肠道息肉发育过程中的血管生成,我们测定了Apc基因敲除(Apc(Delta716))小鼠息肉中的微血管密度(MVD),该小鼠模型用于模拟人类家族性腺瘤性息肉病。我们还对携带Apc(Delta716)的几种复合突变体的MVD进行了评分,即Smad4基因有额外突变的小鼠(其息肉会发展为浸润性腺癌)、环氧化酶(COX)-2基因(Ptgs2)突变的小鼠(其腺瘤生长受到抑制)以及前列腺素E(2) EP受体基因突变的小鼠。在单纯的Apc(Delta716)和复合的Apc(Delta716) Smad4突变体中,仅在直径超过约1 mm阈值而增大的息肉中,MVD以息肉大小依赖的方式增加。这些结果表明,肿瘤血管生成仅在肿瘤生长到一定大小时才被刺激,并且这种血管生成开关在良性腺瘤和恶性腺癌中是共同的。相比之下,在因COX-2基因突变而减轻的Apc(Delta716)息肉病中,即使息肉大于1 mm,MVD也没有增加。在携带Apc(Delta716)和EP(2)受体基因突变的复合突变小鼠中也观察到了相同的现象,但在其他EP复合突变体中未观察到。我们还通过免疫组织化学研究了COX-2和血管生成因子、血管内皮生长因子和碱性成纤维细胞生长因子。有趣的是,这些蛋白的表达在大于1 mm的息肉中也增加。这些结果表明,在良性和恶性小鼠肠道肿瘤中,COX-2的基质表达都会导致前列腺素E(2)水平升高,从而刺激细胞表面受体EP(2),随后诱导血管内皮生长因子,进而导致肿瘤血管生成。